Tc. Heineman et al., A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant, VACCINE, 17(22), 1999, pp. 2769-2778
The safety and immunogenicity of a novel hepatitis B virus (HBV) vaccine co
ntaining recombinant PreS2 and S antigens combined with MF59 adjuvant (HBV/
MF59) was evaluated in healthy adults (N=230) who were randomized to receiv
e 2 or 3 immunizations of either the study vaccine or a licensed control va
ccine (Recombivax HB(R)). After a single immunization, 105 of 118 (89%) rec
ipients of HBV/MF59 achieved protective serum levels of anti-HBs antibody (
>10 mIU/ml), compared with 13 of 110 (12%) recipients of licensed vaccine (
P < 0.001), The geometric mean titer (GMT) after 2 doses of HBV/MF59 given
2 months apart (13,422 mIU/ml) was more than 5-fold higher than that follow
ing 3 doses of licensed vaccine given over 6 months (2,346 mIU/ml; P < 0.00
1). The GMT following 3 injections of HBV/MF59 (249,917 mIU/ml) was 100-fol
d higher than licensed vaccine (P < 0.001), Anti-PreS2 antibodies were elic
ited in over 90% of the subset of HBV/MF59 recipients tested, Both vaccines
were well tolerated; transient, mild-to-moderate local inflammation was th
e major postinjection reaction.(C) 1999 Elsevier Science Ltd. All rights re
served.